CSF3 and breast cancer: In two head-to-head trials, patients with breast cancer received doxorubicin and docetaxel, followed by a G-CSF 24 hours later (either one of: Neulasta®, pegfilgrastim 6 mg once, or 100 mcg/kg once, or filgrastim 5 mcg/kg/day with a mean duration of 11 days) [8].